Free PSA ELISA 试剂盒
This 人 Free PSA ELISA Kit is a Colorimetric ELISA Kit designed to quantify 人 Free PSA.
1 image
Quick Overview for Free PSA ELISA 试剂盒 ()
抗原
See all Free PSA (fPSA) ELISA试剂盒
Free PSA (fPSA)
(Free Prostate Specific Antigen (fPSA))
适用
人
检测方法
Colorimetric
实验类型
Sandwich ELISA
应用范围
ELISA
-
-
Key Features
-
- Frequently cited in scientific publications with 300+ citations
- Validated inhouse for relevant applications
- Extensive validation report for IF provided by one of your peers
- Designed to detect RFP and its variants
-
Key Features
-
- Multiplex ELISA: Testing 5 Targets in 1 Run
- High performance COVID-19 antibody testing
- 99.6% specificity, 95.9% sensitivity
-
Key Features
-
- Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
- Binds SARS-CoV-2 S proteins of lineages B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.617.2 (delta), B.1.1.529 (omicron), B.1.429 (epsilon), B.1.525 (eta), and B.1.617.1 (kappa).
- Frequently used as reference in S-protein ELISAs and neutralization assays.
- Synergizes with other hNAbs: binds a highly conserved epitope, not interefering with the S-protein's ACE2 RBD.
-
Key Features
-
- Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
- Binds SARS-CoV-2 S proteins of lineages B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.429 (epsilon), and B.1.525 (eta).
- Frequently used as reference in S-protein ELISAs and neutralization assays.
- Synergizes with other hNAbs: binds a highly conserved epitope.
- No interference with the ACE2 binding site.
-
Key Features
-
- Dendra2 Antibody (ABIN361314) independently validated for Immunocytochemistry by Neurology Lab (INSERM).
- Publications cite use for Immunoblotting as well as Immunostaining.
- Dendra2 belongs to a new class of photoactivatable fluorescent proteins (PAFPs). PAFPs allow to photolable and track fusion proteins in vivo. Dendra2 Antibody (ABIN361314) can be used for control purposes in this setting.
-
Key Features
-
- Magnetic agarose concanavalin A beads for CUT&RUN and CUT&Tag assays.
- Superior handling compared to magnetic silica concanavalin A beads: easier washes and resuspension.
- Reduced risk for samples to dry out.
- Performance comparable to or better than magnetic silica concanavalin A beads.
-
Key Features
-
- Recombinant SARS-CoV-2 spike protein produced in HEK-293.
- Contains the E484K mutation (present in the novel lineage 501Y.S2 from South Africa) that can affect antibody recognition and enable SARS-CoV-2 immune escape.
- Contains the D614G mutation that renders SARS-CoV-2 infection and replication more efficient.
-
Key Features
-
- Recombinant SARS-CoV-2 spike protein RBD produced in HEK-293.
- Contains the spike protein N501Y mutation (present in the novel lineages B.1.1.7 and 501Y.S2) that has been associated with an increased transmission rate of SARS-CoV-2.
-
Key Features
-
- Recombinant SARS-CoV-2 spike protein RBD produced in HEK-293.
- Contains the spike protein N501Y mutation (present in the novel lineages B.1.1.7 and 501Y.S2) that has been associated with an increased transmission rate of SARS-CoV-2.
-
Key Features
-
- Simultaneous detection of Sp Cas9 binding and cleavage sites in genomic DNA.
- In situ assay leaves cells intact and reduces background.
- Unbiased detection of off-site effects because it is not based on a predictive algorithm.
-
Key Features
-
- Detection of SARS-CoV-2 with variety of different immunoassays, i.e. ELISA, Lateral Flow, as validated by numerous publications (see below).
- Nucleocapsid antibody used for diagnostic Covid19 testing as well as for drug discovery.
- Developed and manufactured in the U.S.
-
Key Features
-
- Has been shown to neutralize SARS-Cov-2 S protein RBD from lineages B.1.1.7, B.1.351, P.1, and B.1.429.
- Suitable as positive control in neutralization antibody screening.
- Humanized chimeric antibody consisting of human IgG1 constant domains and murine variable regions.
-
Key Features
-
- Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.617.
- Contains E154K, L452R, E484Q, D614G, and P681R mutations characteristic for the SARS-CoV-2 kappa variant (B.1.617.1).
-
Key Features
-
- Recombinant trimeric S protein of the SARS-CoV-2 variant of interest B.1.525.
- Contains Q52R, del 69-70, del 144, E484K, F888L, and Q677H mutations characteristic for the SARS-CoV-2 eta variant (B.1.525).
-
Key Features
-
- Recombinant trimeric S protein of the SARS-CoV-2 variant of interest B.1.429.
- Contains S13I, W152C, L452R, and D1183Y mutations characteristic for the SARS-CoV-2 eta variant (B.1.429).
-
Key Features
-
- Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.1.7.
- Contains del 69-70, del 144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H mutations characteristic for the SARS-CoV-2 alpha variant (B.1.1.7).
-
Key Features
-
- Recombinant trimeric S protein of the SARS-CoV-2 variant of concern P.1.
- Contains L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I, and V1176F mutations characteristic for the SARS-CoV-2 gamma variant (P.1).
-
Key Features
-
- Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.617.
- Contains T19R, L452R, T478K, D614G, P681R and D950N mutations characteristic for the SARS-CoV-2 delta variant (B.1.617.2).
-
Key Features
-
- Recombinant trimeric S protein of the SARS-CoV-2 variant of interest B.1.621 mu.
- Contains T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H and D950N mutations characteristic for the SARS-CoV-2 mu variant (B.1.621).
-
Key Features
-
- NLRP3 antibody for reliable recognition of mouse and human NLRP3/NALP3
- This un-conjugated monoclonal antibody has 60 PubMed citations
-
Key Features
-
- 95+ publication references, 1 independent validation
- Frequently used as CUT&RUN IgG negative control and CUT&Tag secondary antibody
- Used in CUT&RUN and CUT&Tag protocols, e.g. Henikoff et al. (2018) PMID 29651053, Kaya-Okur et al. (2019, 2020) PMID 31036827 and PMID 32913232
-
Key Features
-
- Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.1.529 omicron (21K).
- Contains A67V, H69del, V70del, T95I, G142del, V143del, Y144del, Y145D, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, and L981F mutations characteristic for the SARS-CoV-2 omicron variant (B.1.1.529).
-
Key Features
-
- Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.617.2 delta expressed in insect cells.
- Contains T19R, G142D, E156G, FR157-158 deletion, L452R, T478K, D614G, P681R, and D950N mutations characteristic for the SARS-CoV-2 delta variant (B.1.617.2).
- Intact furin cleavage site 680-SRRRAR|SV-687.
- C-terminal His-tag.
-
Key Features
-
- Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.617.2 delta expressed in insect cells.
- Contains EFR157-158 deletion, T19R, G142D, E156G, FR157-158 deletion, L452R, T478K, D614G, P681R, and D950N mutations characteristic for the SARS-CoV-2 delta variant (B.1.617.2).
- Intact furin cleavage site 680-SRRRAR|SV-687.
- C-terminal His-tag.
-
Key Features
-
- Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern P.1 gamma expressed in insect cells.
- Contains L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, and T1027I mutations characteristic for the SARS-CoV-2 gamma variant (P.1).
- Intact furin cleavage site 680-SPRRAR|SV-687.
- C-terminal His-tag.
-
Key Features
-
- Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern P.1 gamma expressed in insect cells.
- Contains L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F mutations characteristic for the SARS-CoV-2 gamma variant (P.1).
- Intact furin cleavage site 680-SPRRAR|SV-687.
- C-terminal His-tag.
-
Key Features
-
- Recombinant S protein S1+S2 (M1-P1213) of the SARS-CoV-2 variant of concern B.1.351 expressed in insect cells.
- Contains D80A, K417N, E484K, N501Y, D614G, and A701V mutations characteristic for the SARS-CoV-2 beta variant (B.1.351).
- Intact furin cleavage site 680-SPRRAR|SV-687.
- C-terminal His-tag.
-
Key Features
-
- Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.351 expressed in insect cells.
- Contains L18F, D80A, D215G, LAL242-244 deletion, R246I, K417N, E484K, N501Y, D614G, and A701V mutations characteristic for the SARS-CoV-2 beta variant (B.1.351).
- Intact furin cleavage site 680-SPRRAR|SV-687.
- C-terminal His-tag.
-
Key Features
-
- Recombinant S protein S1+S2 (M1-P1213) of the SARS-CoV-2 variant of concern B.1.351 expressed in insect cells.
- Contains L18F, D80A, D215G, LAL242-244 deletion, R246I, K417N, E484K, N501Y, D614G, and A701V mutations characteristic for the SARS-CoV-2 beta variant (B.1.351).
- Intact furin cleavage site 680-SPRRAR|SV-687.
- C-terminal His-tag.
-
Key Features
-
- Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.1.7 expressed in insect cells.
- Contains HV69-70 deletion, Y145 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H characteristic for the SARS-CoV-2 alpha variant (B.1.1.7).
- Intact furin cleavage site 680-SHRRAR|SV-687.
- C-terminal His-tag.
-
Key Features
-
- Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.1.7 expressed in insect cells.
- Contains HV69-70 deletion, Y144 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H characteristic for the SARS-CoV-2 alpha variant (B.1.1.7).
- Intact furin cleavage site 680-SHRRAR|SV-687.
- C-terminal His-tag.
-
Key Features
-
- Recombinant SARS-CoV-2 wt S protein S1+S2 (M1-P1213) expressed in insect cells.
- Contains D614G mutation.
- Intact furin cleavage site 680-SPRRAR|SV-687.
- C-terminal His-tag.
-
Key Features
-
- High-affinity single-domain antibody
- Recognizes mRFP, mCherry, mScarlet-i, tdTomato, dsRed etc.
- Bead size 50-150 μm
-
Key Features
-
- Monoclonal murine neutralizing antibody (nAb) against SARS-CoV-2 S protein.
- Binds SARS-CoV-2 S proteins of various lineages, including B.1.617.2 (delta) and B.1.1.529 (omicron).
- Ideal for SARS-CoV-2 S-protein ELISAs and neutralization assays.
-
Key Features
-
- Monoclonal murine neutralizing antibody (nAb) against SARS-CoV-2 S protein.
- Binds SARS-CoV-2 S proteins of various lineages, including B.1.617.2 (delta). Does NOT bind the S protein of SARS-CoV-2 B.1.1.529 (omicron).
- Ideal for SARS-CoV-2 S-protein ELISAs and neutralization assays.
-
Key Features
-
- Rabbit beta-Catenin antibody reliably detects beta-Catenin targets in Wnt-signaling using CUT&RUN, ICC, IF, WB, ELISA.
- Well suited to image adherens junctions in IHC/IF.
- Highly specific beta-Catenin detection in WB.
-
Key Features
-
- Rabbit anti-CRBN Antibody reliably detects CRBN in human species.
- Polyclonal, unconjugated antibody for ELISA, WB, IHC.
- Highly specific CRBN detection. See validation images.
-
Key Features
-
- Mouse IL-1 beta ELISA kit for quantitative detection of IL-1 beta.
- Reliable product with validated components.
- ELISA kit cited in more than 40 PubMed References.
-
Key Features
-
- Magnetic agarose Concanavalin A beads for affinity chromatography using a magnetic separator.
- Easy bench-top purification of viruses, virus-like particles (VLP), and cultured cells via reversible binding of glycoproteins, glycolipids, or polysaccharides with terminal mannose or glucose to concanavalin A.
-
Key Features
-
- Polyclonal, unconjugated GFP antibody for reliable detection of GFP and its variants.
- Validated for Fluorescence Microscopy, ELISA, Western Blotting
- High Quality GFP antibody, cited in more than 177 PubMed References.
- Available in 10 µl and 100 µl quantities.
-
Key Features
-
- Reliable Taurine Assay Kit for measurement of free taurine in biological samples.
- Sample taurine concentrations are determined by comparison with a known taurine standard.
- Quick and easy to use.
-
Key Features
-
- Impurity detection in the manufacturing of biological drugs.
- The AccuSignal™ Nuclease ELISA Kit is designed for sensitive and reliable quantification of nucleases in therapeutic products, including DENARASE®, Benzonase®, and Turbonuclease.
- Offers a broad quantification spectrum, maintaining outstanding dilution linearity, instilling trust in the accuracy of results over a wide array of nuclease concentrations.
- Delivers consistent and repeatable outcomes, characterized by minimal intra- and inter-assay variability.
- Tailored antibody specificity allows for application across diverse materials, accommodating various nuclease products from multiple suppliers.
- Components: 96-well strip plate, plate sealer, nuclease standard, biotinylated detection antibody, Streptavidin-HRO (100X), buffers.
-
Key Features
-
- High-affinity anti-GFP single-domain antibody (sdAb) covalently bound to 4 % cross-linked agarose magnetic beads with 50-150 µm diameter.
- The Alpaca sdAb clone 1H1 is specific for GFP and many GFP derivatives. Capacity > 3 μg GFP per μl of packed beads.
- Compatible with physiological buffers, common Lysis and Wash Buffers, and high stringency buffers.
-
Key Features
-
- High-quality FcRn antibody (Clone ADM31) for the detection of FcRn.
- Highly specific for human FcRn, blocks the binding of human serum albumin.
- PBS-only, preservative free
- 15 PubMed references available for this FcRn antibody.
-
Key Features
-
- High-quality FcRn antibody (Clone DVN24) for the detection of FcRn.
- Highly specific for human FcRn, blocks the binding of IgG.
- PBS-only, preservative free
- 2 PubMed references available for this FcRn antibody.
-
Key Features
-
- High-affinity anti-GFP single-domain antibody (sdAb) covalently bound to 4 % cross-linked agarose beads with 50-150 µm diameter.
- The Alpaca sdAb clone 1H1 is specific for GFP and many GFP derivatives. Capacity > 3 μg GFP per μl of packed beads.
- Compatible with physiological buffers, common Lysis and Wash Buffers, and high stringency buffers.
-
Key Features
-
- TrueBlot®: Anti-Rabbit IgG HRP, Mouse Monoclonal eB182
- Manufactured by Rockland Immunochemicals, Inc.
- Rockland Product ID: 18-8816-33
-
Key Features
-
- TrueBlot®: Anti-Rabbit IgG HRP, Mouse Monoclonal eB182
- Manufactured by Rockland Immunochemicals, Inc.
- Rockland Product ID: 18-8816-31
-
Key Features
-
- Anti-ATM Protein Kinase pS1981 (MOUSE) Monoclonal Antibody
- Manufactured by Rockland Immunochemicals, Inc.
- Rockland Product ID: 200-301-400
-
Key Features
-
- High-quality FcRn antibody (Clone ADM31) for the detection of FcRn.
- Highly specific for human FcRn, blocks the binding of human serum albumin.
- contains Glycerol for better storage.
-
Key Features
-
- High-quality FcRn antibody (Clone DVN24) for the detection of FcRn.
- Highly specific for human FcRn, blocks the binding of IgG.
- Contains Glycerol for better storage.
-
原理
- Immunoenzymometric assay (TYPE 3): The essential reagents required for an immunoenzymometric assay include high affinity and specificity antibodies (enzyme and immobilized), with different and distinct epitope recognition, in excess, and native antigen. In this procedure, the immobilization takes place during the assay at the surface of a microplate well through the interaction of streptavidin coated on the well and exogenously added biotinylated monoclonal anti-PSA antibody. Upon mixing monoclonal biotinylated antibody, the enzyme-labeled antibody and a serum containing the native antigen, reaction results between the native antigen and the antibodies, without competition or steric hindrance, to form a soluble sandwich complex. After equilibrium is attained, the antibodybound fraction is separated from unbound antigen by decantation or aspiration. The enzyme activity in the antibodybound fraction is directly proportional to the native antigen concentration. By utilizing several different serum references of known antigen values, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.
-
Analytical Method
- Quantitative
-
组件
- A. f-PSA Calibrators (1ml/vial). Six vials of references free PSA antigen at levels of 0 (A), 0. 5 (B), 1. 0 (C), 2. 5 (D), 5. 0 (E) and 10. 0 (F) ng/ml. Store at 2-8°C. A preservative has been added. Note: The calibrators, protein based buffered matrix, were calibrated using a reference preparation, which was assayed against the WHO 1st International Standard 96/668. B. fPSA Enzyme Reagent (13 ml/vial). One vial containing enzyme labeled antibody, biotinylated specific free PSA monoclonal mouse IgG in buffer, dye, and preservative. Store at 2-8°C. C. Streptavidin Coated Plate (96 wells). One 96-well microplate coated with streptavidin and packaged in an aluminum bag with a drying agent. Store at 2-8°C. D. Wash Solution Concentrate (20 ml). One vial containing a surfactant in buffered saline. A preservative has been added. Store at 2-30°C. E. Substrate A (7ml/vial). One bottle containing tetramethylbenzidine (TMB) in buffer. Store at 2-8°C. F. Substrate B (7ml/vial). One bottle containing hydrogen peroxide (H2O2) in buffer. Store at 2-8°C. G. Stop Solution (8ml/vial). One bottle containing a strong acid (1N HCl). Store at 2-30°C. I. Product Instructions: Note 1: Do not use reagents beyond the kit expiration date. Note 2: Opened reagents are stable for 60 days when stored at 2-8°C. Note 3: See end of this product insert for various configurations of reagents by kit size.
-
试剂未包括
- 1. Pipette capable of delivering 50µl volumes with a precision of better than 1. 5%. 2. Dispenser(s) for repetitive deliveries of 0. 100ml and 0. 350ml volumes with a precision of better than 1. 5%. 3. Microplate washers or a squeeze bottle (optional). 4. Microplate Reader with 450nm and 620nm wavelength absorbance capability. 5. Absorbent Paper for blotting the microplate wells. 6. Plastic wrap or microplate cover for incubation steps. 7. Vacuum aspirator (optional) for wash steps. 8. Timer. 9. Quality control materials.
-
Product Specific Information
-
Our GFP Catcher is a product based on the GFP pull-down technique used to isolate GFP fusion proteins from cell lysates. It consists of special magnetic beads (product ABIN7272855) or agarose beads (product ABIN5311508) coated with an antibody against GFP. These beads allow efficient and selective binding to GFP or GFP-fused target proteins.
The application of GFP Catcher is similar to the GFP pull-down method. First, the protein of interest is expressed in the cells with it fused to GFP. Then, the cell lysate is prepared to extract the target proteins. The GFP catcher beads are then added to the cell lysate and bound to these proteins by specifically binding to the GFP or GFP fusion protein.
After the beads with the bound target proteins are isolated, thorough purification is performed to remove components that are not specifically bound. Finally, the target proteins can be separated from the beads and used for further analysis such as immunoblotting or mass spectrometry.
GFP Catcher offers the advantage of quick and easy isolation of GFP fusion proteins. It is a useful tool for protein analysis and allows efficient identification of proteins interacting with GFP fusion protein. GFP Catcher is widely used in cell biology research to study protein-protein interactions and deepen the understanding of cellular processes.
-
-
Free Prostate Specific Antigen (fPSA) ELISA Kit
fPSA 适用: 人 Colorimetric Sandwich ELISA 0.156 ng/mL - 10 ng/mL Plasma, Serum, Tissue Homogenate
Free Prostate Specific Antigen (fPSA) ELISA KitfPSA 适用: 人 Colorimetric Sandwich ELISA 45-12.000 pg/mL Cell Culture Supernatant, Plasma, Serum
-
-
应用备注
- Precautions: All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA required tests. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, Biosafety in Microbiological and Biomedical Laboratories, 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.
-
样本量
- 25 μL
-
板类型
- Pre-coated
-
试剂准备
-
- Wash Buffer: Dilute contents of wash concentrate to 1000 ml with distilled or deionized water in a suitable storage container. Store at room temperature (20-27°C) for up to 60 days. 2. Working Substrate Solution: Pour the contents of the amber vial labeled Solution A into the clear vial labeled Solution B. Place the yellow cap on the clear vial for easy identification. Mix and label accordingly. Store at 2 - 8 °C. Note: Do not use the working substrate if it looks blue.
-
样品收集
- The specimens shall be blood, serum in type and the usual precautions in the collection of venipuncture samples should be observed. For accurate comparison to established normal values, a fasting morning serum sample should be obtained. The blood should be collected in a plain redtop venipuncture tube without additives or anti-coagulants. Allow the blood to clot. Centrifuge the specimen to separate the serum from the cells. Samples may be refrigerated at 2-8°C for a maximum period of five days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20 °C for up to 30 days. Avoid repetitive freezing and thawing. When assayed in duplicate, 0. 100ml of the specimen is required.
-
结果分析
-
A dose response curve is used to ascertain the concentration of fPSA in unknown specimens. 1. Record the absorbance obtained from the printout of the microplate reader. 2. Plot the absorbance for each duplicate serum reference versus the corresponding fPSA concentration in ng/ml on linear graph paper (do not average the duplicates of the serum references before plotting). 3. Draw the best-fit curve through the plotted points. 4. To determine the concentration of fPSA for an unknown, locate the average absorbance of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in ng/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). Note: Computer data reduction software designed for ELISA assays may also be used for the data reduction.
-
限制
- 仅限研究用
-
-
-
注意事项
- Before proceeding with the assay, bring all reagents, serum references and controls to room temperature (20-27°C). 1. Format the microplates' wells for each serum reference, control and patient specimen to be assayed in duplicate. Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C. 2. Pipette 0. 050 ml (50µl) of the appropriate serum reference, control or specimen into the assigned well. 3. Add 0. 100 ml (100µl) of the fPSA Enzyme Reagent to each well. It is very important to dispense all reagents close to the bottom of the coated well. 4. Swirl the microplate gently for 20-30 seconds to mix and cover. 5. Incubate 60 minutes at room temperature (20-27°C). 6. Discard the contents of the microplate by decantation or aspiration. If decanting, tap and blot the plate dry with absorbent paper. 7. Add 350µl of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two additional times for a total of three washes. An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and Repeat two additional times. 8. Add 0. 100 ml (100µl) of working substrate solution to all wells (see Reagent Preparation Section). Always add reagents in the same order to minimize reaction time differences between wells. DO NOT SHAKE THE PLATE AFTER SUBTRATE ADDITION. 9. Incubate at room temperature for 15 minutes. 10. Add 0. 050ml (50µl) of stop solution to each well and mix gently for 15-20 seconds. Always add reagents in the same order to minimize reaction time differences between wells. 11. Read the absorbance in each well at 450nm (using a reference wavelength of 620-630nm to minimize well imperfections) in a microplate reader. The results should be read within 30 minutes of adding the stop solution.
-
储存条件
- 4 °C/-20 °C
-
-
- Free PSA (fPSA) (Free Prostate Specific Antigen (fPSA))
-
别名
- Prostate Specific Antigen (PSA) (free)
-
背景
- Summary and Explanation of the test: Prostate Specific antigen (PSA) is a serine protease with chymotrypsin-like activity (1,2). The protein is a single chain glycoprotein with a molecular weight of 28. 4 kDA (3). PSA derives its name from the observation that it is a normal antigen of the prostrate but is not found in any other normal or malignant tissue. PSA is released from the normal prostate and appears at low serum concentrations in healthy men. Studies with reverse transcription-PCR have shown that PSA also is expressed at a low concentration in peripheral blood cells and other tissues (4). High serum concentrations can be detected in patients with advanced prostate cancer (PCA) (5). Therefore PSA is applied as a tumor marker for the clinical management of PCA (6). However, increased PSA concentrations in serum also occur in patients with benign prostate hyperplasia (BPH) (7). Hence the goal is to discriminate clearly between BPH and PCA in the clinical laboratory to spare the patient invasive diagnostic procedures, such as a prostate biopsy. In human serum PSA occurs in two forms: free PSA (f-PSA) and complexed PSA. The major form is a complex of PSA and a1-antichymotrypsin (ACT). The fraction of f-PSA was shown to be substantially smaller in patients with untreated PCA than in patients with BPH. Therefore combined measurements of f-PSA and total PSA (t-PSA) may lead to a better discrimination between BPH and PCA Some recent studies have already shown that the f-PSA/t-PSA ratio is helpful in the differential diagnosis of BPH and PCA. PSA is found in benign, malignant and metastatic prostrate cancer. Since prostate cancer is the second most prevalent form of male malignancy, the detection of elevated PSA levels plays an important role in the early diagnosis. Serum PSA levels have been found to be more useful than prostatic acid phosphatase (PAP) in the diagnosis and management of patients due to increased sensitivity (4). In this method, fPSA calibrator, patient specimen or control is first added to a streptavidin coated well. Biotinylated monoclonal and enzyme labeled antibodies (directed against distinct and different free epitopes of fPSA) are added and the reactants mixed. Reaction between the various PSA antibodies and native PSA forms a sandwich complex that binds with the streptavidin coated to the well. After the completion of the required incubation period, the enzyme-fPSA antibody bound conjugate is separated from the unbound enzyme-fPSA conjugate by aspiration or decantation. The activity of the enzyme present on the surface of the well is quantitated by reaction with a suitable substrate to produce color. The employment of several serum references of known prostate specific antigen (fPSA) levels permits the construction of a dose response curve of activity and concentration. From comparison to the dose response curve, an unknown specimen's activity can be correlated with fPSA concentration. Intended Use: The Quantitative Determination of Free Prostrate Specific Antigen (fPSA) Concentration in Human Serum by a Microplate Immunoenzymometric assay. Q. C. Parameters: In order for the assay results to be considered valid the following criteria should be met: 1. The absorbance (OD) of calibrator F should be greater than 1.3. 2. Four out of six quality control pools should be within the established ranges.
抗原 See all Free PSA (fPSA) ELISA试剂盒
-
You are here:
